Stock Taper
SCREENER COMPARE ANY 2 STOCKS
NKTR
NEKTAR THERAPEUTICS
NASDAQ
$72.52
▼ DOWN 2.72% (-2.03)

KEY STATISTICS

Market Cap$2.08 B
52w High$109.00
52w Low$27.87
Dividend Yield—
Frequency—
P/E-10.86
Volume579.63K
Shares Out.28.69M

COMPANY

LEADERSHIP

Howard W. Robin
CHIEF EXECUTIVE
Howard W. Robin

COMPENSATION 2026

Salary$1,106,282
Stock Awards$942,081
Incentive Plan Pay$1,106,282
All Other Comp.$115,774
Total$6,256,954

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 3, 1994
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
63

PRICE TARGET

Target High$192.00
Target Low$80.00
Target Median$153.00
Target Consensus$150.00

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$10.41M
NOV
5
THU

SPLIT RECORD

DATETYPERATIO
2025-06-09Reverse1:15
2000-08-23Forward2:1

PRICE

$72.52 ▼ DOWN 2.72% (−$2.03)
OVERLAYS
$72.00$73.50$75.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM72.52

About Nektar Therapeutics

https://www.nektar.com ↗

Nektar Therapeutics is a San Francisco-based biopharma company developing innovative medicines, including immunotherapies and cytokine treatments, for various cancers, autoimmune diseases, and COVID-19, through multiple clinical trial stages and c...

INDUSTRY

Biotechnology

A PRODUCT NEKTAR THERAPEUTICS IS KNOWN FOR

Rezpegaldesleukin (NKTR-358)
Rezpegaldesleukin (NKTR-358)

Rezpegaldesleukin, Nektar Therapeutics' lead investigational therapy, aims to restore immune balance by stimulating regulatory T cells and is in mid-to-late stage trials for autoimmune and inflammatory diseases.

COMPETITORS

COMPETITOR
COYA COMPARE
CRVS COMPARE
REGN COMPARE
SNY COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Non Cash Royalty Revenue Related To Sale Of Future Royalties$11.49M $21.81M ▲$10.86M ▼$10.13M ▼
License Collaboration And Other Revenue$300K $0 ▼— —

Revenue by Geography

MapREGIONFY2022FY2023FY2024FY2025
NonUS$82.21M $78.64M ▼$97.05M ▲$55.23M ▼
UNITED STATES$9.84M $11.48M ▲$1.38M ▼—

ETFS HOLDING THIS STOCK

ETFS HOLDING
113
LISTED HERE
24
RANKED BY POSITION SIZE
VTS.AX
0.00% · 1.1M
XSU.TO
0.08% · 884.5K
SCHA
0.05% · 160.9K
XPH
1.87% · 146.9K
CN
CNCR
3.37% · 87.5K
PRFZ
0.16% · 59.6K
OR
ORR
1.21% · 59.4K
LFSC
3.01% · 52.6K
SBIO
1.25% · 41.7K
XRS2.F
0.08% · 31.5K
RSSL
0.08% · 16.5K
FHLC
0.03% · 14.7K
SP
SPIT
2.12% · 10.0K
BBSC
0.08% · 8.3K
AVSC
0.01% · 5.9K
BBC
0.75% · 5.3K
PILL
1.25% · 4.1K
FSML
0.10% · 2.1K
URTY
0.03% · 1.4K
RFLR
0.08% · 1.0K
TILT
0.00% · 810
TMFX
0.11% · 512
USFMDN.MX
0.01% · 155
RESM
0.11% · 94

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
402
TOP 12 OF 402 · RANKED BY POSITION SIZE
Oppenheimerfunds, Inc.
17.3M sh · $581.38M
Blackrock Inc.
15.2M sh · $18.79M
Blackrock Fund Advisors
13.8M sh · $169.86M
Fmr LLC
5.1M sh · $353.79M
Blackrock Institutional Trust Company, N.A.
3.8M sh · $46.08M
Two Seas Capital LP
3.1M sh · $215.87M
Blackrock, Inc.
2.9M sh · $205.37M
Bvf Inc/Il
2.6M sh · $184.16M
Invus Public Equities Advisors, LLC
2.5M sh · $18.54K
Bb Biotech AG
2.0M sh · $67.89M
Janus Henderson Investors Us LLC
1.7M sh · $40.13M
Lehman Brothers Holdings Inc. Plan Trust
1.7M sh · $5.61K

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF R&D OFFICER
Zalevsky Jonathan
Sale · 186 shares
2026-08-18
★
DIRECTOR, OFFICER: PRESIDENT & CEO
ROBIN HOWARD W
Sale · 418 shares
2026-08-18
★
OFFICER: CHIEF R&D OFFICER
Zalevsky Jonathan
Purchase · 16.5K shares
2026-07-24
★
DIRECTOR, OFFICER: PRESIDENT & CEO
ROBIN HOWARD W
Purchase · 57.2K shares
2026-07-24

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 5
NEUTRAL 1
OVERWEIGHT 1
7 GRADES IN THE LAST 12 MONTHS
Wedbush NEUTRAL Piper Sandler OVERWEIGHT Citigroup BUY BTIG BUY HC Wainwright & Co. BUY B. Riley Securities BUY Jefferies BUY

SECTORS PEERS

PEERPRICE
ELVN$57.86COMPARE
RLAY$18.77COMPARE
AMLX$34.74COMPARE
ATAI$7.29COMPARE
XNCR$26.06COMPARE
INBX$123.41COMPARE
SNDX$19.54COMPARE
ORIC$13.24COMPARE